drugset

drugset / Trial / NCT05052268

XTX202 in Patients With Advanced Solid Tumors

NCT05052268 ↗

Phase 1/2 Completed 95 enrolled Xilio Development, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors

Timeline

Start: 2022-01-18
Primary completion: 2025-03-22
Completion: 2025-03-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	XTX202	Protein / enzyme biologic	—	—

Indications